Other formats:
BibTeX
LaTeX
RIS
@proceedings{1084974,
author = {Weber, Pavel and Meluzínová, Hana and Hrubanová, Jana and Matějovská Kubešová, Hana and Polcarová, Vlasta and Weberová, Dana},
booktitle = {6th European Congress of Pharmacology – EPHAR 2012},
keywords = {Long-term Anticoagulant Therapy - Warfarin - Drug Interactions - Risks - Bleeding - Atrial Fibrilation},
language = {eng},
title = {Long-term Anticoagulant Therapy with Warfarin and its Risks and Pitfalls in Old Age},
year = {2012}
}
TY - CONF
ID - 1084974
AU - Weber, Pavel - Meluzínová, Hana - Hrubanová, Jana - Matějovská Kubešová, Hana - Polcarová, Vlasta - Weberová, Dana
PY - 2012
TI - Long-term Anticoagulant Therapy with Warfarin and its Risks and Pitfalls in Old Age
KW - Long-term Anticoagulant Therapy - Warfarin - Drug Interactions - Risks - Bleeding - Atrial Fibrilation
N2 - Warfarin is a frequently used anticoagulant therapy (AT) in clinical practice for elderly patients at risk of thromboembolism (venous or arterial) as well as for those with established thromboembolism. Bleeding is the most common complication of long-term warfarin therapy. The risk of bleeding is directly influenced by intensity of anticoagulant therapy, age, renal insufficiency, and latent disease of the gastrointestinal and genitourinary tracts. Conclusions: Most elderly patients in need of prolonged anticoagulation can be treated safely and effectively with warfarin if treatment includes education, meticulous attention to comorbid illnesses and concomitant drugs, and dose monitoring through a coordinated anticoagulant program.
ER -
WEBER, Pavel, Hana MELUZÍNOVÁ, Jana HRUBANOVÁ, Hana MATĚJOVSKÁ KUBEŠOVÁ, Vlasta POLCAROVÁ and Dana WEBEROVÁ. Long-term Anticoagulant Therapy with Warfarin and its Risks and Pitfalls in Old Age. In \textit{6th European Congress of Pharmacology – EPHAR 2012}. 2012.
|
